MedPath

Study of Picoplatin Efficacy After Relapse

Phase 3
Conditions
Small Cell Lung Cancer
Interventions
Other: best supportive care
Registration Number
NCT00465491
Lead Sponsor
Poniard Pharmaceuticals
Brief Summary

Picoplatin is a new type of platinum drug that has been investigated in several clinical trials, and may provide an improved safety profile over current treatment options. This study is designed to compare the efficacy and safety of picoplatin plus Best Supportive Care (BSC) with BSC alone. Best Supportive Care includes care and treatment to optimize the comfort of patients and their ability to function, as well as to minimize the side-effects of anti-cancer treatments.

Detailed Description

This Phase 3 study will enroll subjects with Small Cell Lung Cancer (SCLC) who are refractory or progressive within 6 months of completing first-line, platinum-containing chemotherapy. Subjects will be centrally randomized 2:1 to receive picoplatin plus BSC every 3 weeks, or BSC alone. After discontinuation of picoplatin, all subjects will continue to receive BSC and will continue to be evaluated every 3 weeks until discontinuation from the study, death, or the end of the study. After discontinuation of picoplatin, subjects may be treated with another chemotherapy at their physician's discretion and then will be followed for survival.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
399
Inclusion Criteria
  • Histological or cytological diagnosis of SCLC or combined SCLC/non-small cell lung cancer (NSCLC) defined as SCLC mixed with squamous cell carcinoma, adenocarcinoma, or large cell carcinoma.
  • One and only 1 prior cisplatin or carboplatin-containing chemotherapy regimen for SCLC within the scope of the National Comprehensive Cancer Network (NCCN) Guidelines (Section 5.4.1).
  • Radiological evidence of SCLC that never responded or progressed within 90 days after completion of first-line therapy (refractory); or responded initially to first-line therapy but progressed between 91 and 180 days after treatment was completed (progressed within 91 to 180 days).
  • CT scans of head, chest and abdomen (including adrenal and full extent of liver) with contrast, preferably within 14 days prior to randomization (up to 21 days is allowed if necessary). MRI is acceptable in the case of allergy to contrast agents. The presence or absence of measurable disease gy RECIST must be documented from the baseline CT or MRI scan.
  • Patients with brain metastases must have been treated with brain irradiation. Only patients wtih asymptomatic brain metastases are eligible for this study.
  • ECOG PS 0, 1 or 2 within 3 days prior to randomization (Appendix II).
  • Life expectancy of at least 8 weeks within 3 days prior to randomization.
  • At least 21 days must have elapsed since the most recent prior chemotherapy dose, with evidence of hematological recovery.
  • At least 14 days must have elapsed since the most recent prior radiotherapy dose.
  • At least 14 days must have elapsed since prior surgery except for the placement of venous access device or bronchoscopy.
  • Subject must be recovered to ≤ Grade 1 toxicity from all non-hematological adverse effects of prior therapies (excluding alopecia).
  • Age 18 years or over.
  • ANC ≥ 1.5 x 109/L.
  • Platelet count ≥ 100 x 109/L.
  • Hemoglobin of ≥ 90 g/L (transfusion permitted to achieve this hemoglobin).
  • Aspartate aminotransferase, alanine aminotransferase, and lactate dehydrogenase levels ≤ 2.5 times upper limit of normal (ULN) or ≤ 5 times ULN if liver involvement is present.
  • Bilirubin of ≤ 1.5 times upper limit of normal (ULN).
  • Blood urea nitrogen ≤ 1.5 times ULN (hypovolemic subjects may be hydrated to achieve this BUN).
  • Creatinine clearance of ≥ 50 mL/min, as calculated by the Cockcroft-Gault formula (Appendix III).
  • Women of childbearing potential must have a negative pregnancy test (serum or urine). Sexually active couples of child-bearing potential must agree to use appropriate birth control methods during chemotherapy and for 3 months after chemotherapy.
  • Signed informed consent.
Exclusion Criteria
  • Prior radiotherapy that included ≥ 30% of the bone marrow (Appendix IV).
  • Pleural effusion as the only radiological evidence of SCLC.
  • Untreated or symptomatic brain or central nervous system (CNS) metastases.
  • Grade 2 or higher peripheral neuropathy.
  • Significant cardiac disease, defined as myocardial infarction within 3 months prior to randomization, congestive heart failure classified by the New York Heart Association as Class III or IV (Appendix V), uncontrolled cardiac arrhythmias, poorly controlled or unstable angina, or electrocardiographic evidence of acute ischemia.
  • Serious medical or psychiatric illness that could potentially interfere with the completion of study treatment according to this protocol, e.g., active infection, Crohn's disease, ulcerative colitis, etc.
  • Use of other investigational drugs within 30 days prior to randomization.
  • Breast-feeding.
  • History of any other malignancy within 5 years, with the exception of treated non-melanoma skin cancer or carcinoma in situ of the cervix.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1picoplatinPicoplatin
2best supportive careBSC
Primary Outcome Measures
NameTimeMethod
overall survivaldeath
Secondary Outcome Measures
NameTimeMethod
duration of responseprogression
progression-free survivaldeath
objective response rateprogression
disease control rateprogression

Trial Locations

Locations (138)

Gujrat Cancer Research Institute

🇮🇳

Asarwa, Ahmadabad, India

Centro Oncologico

🇦🇷

Buenos Aires, Argentina

Instituto Alexander Fleming

🇦🇷

Buenos Aires, Argentina

Gomel Regional Oncological Dispensary

🇧🇾

Gomel, Belarus

Vitebsk Regional Oncology Dispensary

🇧🇾

Vitebsk, Belarus

Regional Oncodispensary with Inpatient Sector

🇧🇬

Rousse, Bulgaria

Special Hospital for Pulmonary Diseases

🇲🇪

Niksic, Montenegro

Clinical Hospital Split

🇭🇷

Split, Croatia

General Rehablitation and Medicinal Bath Hospital

🇭🇺

Szombathely, Hungary

Mahaveer Cancer Sansthan

🇮🇳

Patna, India

Jahangir Hospital and Research Centre

🇮🇳

Pune, India

Paul Stradins Clincial University Hospital

🇱🇻

Riga, Latvia

Smt. Vasantben R. Desai Cancer Research Center

🇮🇳

Rajkot, India

Regional Cancer Centre

🇮🇳

Trivandrum, India

IANULI Medconsult SRL

🇷🇴

Bucharest, Romania

Komi Republican Oncology Center

🇷🇺

Syktyvkar, Komi Republic, Russian Federation

Chita Regional Oncology Center

🇷🇺

Chita, Russian Federation

Magnitogorsk Clinical Oncology Hospital

🇷🇺

Magnitogorsk, Russian Federation

Central Clinical Hospital and Outpatient Unit of the Medical Center under the Russian Presidential Administration

🇷🇺

Moscow, Russian Federation

City Oncology Center

🇷🇺

Komsomolsk-na-Amure, Russian Federation

Regional Clinical Hospital #1

🇷🇺

Krasnodar, Russian Federation

Novorossiysk Oncology Center

🇷🇺

Novorossiysk, Russian Federation

Semashko Central Clinical Hospital #2 under Russian Railways

🇷🇺

Moscow, Russian Federation

City Clinical Hospital #1

🇷🇺

Novosibirsk, Russian Federation

Medical Radiology Research Center under RAMS

🇷🇺

Obnninsk, Russian Federation

Tula Regional Oncology Center

🇷🇺

Tula, Russian Federation

Ufa, Republican Oncology Center

🇷🇺

Ufa, Russian Federation

Volgograd Regional Clinical Oncology Center#1

🇷🇺

Volograd, Russian Federation

Clinic for Pulmonary Diseases and TBC

🇷🇸

Knez Selo, Serbia

Institute for Pulmonary Diseases of Vijvodina

🇷🇸

Vijvodina, Serbia

Volyn Regional Oncology Center

🇺🇦

Lutsk, Ukraine

Sumy Regional Oncology Center

🇺🇦

Sumy, Ukraine

Ternopol Regional Clinical Oncology Center

🇺🇦

Ternopol, Ukraine

Zaporozhye Regional Clinical Oncology Center

🇺🇦

Zaporozhye, Ukraine

CETEN Centro de Estudio y Tratamiento de Enfermedades Neoplasicas

🇦🇷

Buenos Aires, Argentina

IADT (Insttituto Argentino de Diagnostico y Tratamiento S.A.)

🇦🇷

Buenos Aires, Argentina

Consultorios Privados

🇦🇷

Buenos Aires, Argentina

Clinica Constituyentes

🇦🇷

Buenos Aires, Argentina

Centro Oncologico de Rosario

🇦🇷

Santa Fe, Argentina

PALIAR

🇦🇷

Buenos Aires, Argentina

Centro Medico San Roque

🇦🇷

Tucuman, Argentina

Minsk City Clinical Oncology Dispensary

🇧🇾

Minsk, Belarus

IONC

🇦🇷

Cordoba, Argentina

Research Institute of Oncology and Medical Radiology named by N.N. Aleksandrov

🇧🇾

Minsk, Belarus

Clinic for Lung Diseases, Clinical Center, Banja Luka

🇧🇦

Banja Luka, Bosnia and Herzegovina

University Multifunctional Hospital for Active Treatment "Dr. Georgi Stranski"

🇧🇬

Pleven, Bulgaria

Clinic of Pulmonary Diseases Podhrastovi

🇧🇦

Sarajevo, Bosnia and Herzegovina

Multiprofile Hospital for Active Treatment, Dr. Tota Venkova

🇧🇬

Gabrovo, Bulgaria

Regional Oncodispensary with Inpatient Sector-Sofia District

🇧🇬

Sofia, Bulgaria

Instituto Nacional de Cancer

🇨🇱

Santiago, Chile

St. George County Hospital

🇭🇺

Fejer County, Hungary

Clinical Hospital

🇭🇷

Osijek, Croatia

Apollo Speciality Hospital

🇮🇳

Chennai, India

Yashoda Group of Hospitals

🇮🇳

Hyderabad, India

Orchid Nursing Home

🇮🇳

Kolkata, India

Sir Ganga Ram Hospital

🇮🇳

New Delhi, India

Jawaharlal Nehru Cancer Hospital and Research Centre

🇮🇳

Bhopal, India

Indo American Institute of Oncology

🇮🇳

Hyderabaad, India

SEAROC Cancer Center

🇮🇳

Jaipur, India

MNJ Institute of Oncology

🇮🇳

Hyderabaad, India

King George Medical University

🇮🇳

Lucknow, India

KMC (Karturba Medical College) Hospital

🇮🇳

Manipal, India

Rajiv Gandhi Cancer Institute, Delhi

🇮🇳

New Delhi, India

King George Hospital

🇮🇳

Vishakhapatnam, India

Daugavas Hospital

🇱🇻

Daugavpils, Latvia

Dolnoslaskie Centre of Lung Diseases

🇵🇱

Wroclaw, Dolnoslaskie, Poland

NMP, Memorial Voyvodship Hospital

🇵🇱

Czestochowa, Poland

Kujawsko-Pomorski Centre of Pulmonology

🇵🇱

Bydgoszcz, Poland

Independent Public Group for Tuberculosis and Lung Disease in Olsztyn

🇵🇱

Olsztyn, Poland

Department of Clinical Oncology, Wielkopolskie Centre of Lung Diseases and Tuberculosis

🇵🇱

Poznan, Poland

Conservative Outpatient Oncology Department, Voyevodship Hospital in Plock

🇵🇱

Plock, Poland

Medical Oncology Center Iasi

🇷🇴

Iasi, Romania

SP ZOZ Voyevodship Specialistic Hospital #3

🇵🇱

Rybnik, Poland

Department of Chemotherapy, Prof. A. Sokolowski Memorial Specialistic Hospital in Szczecin

🇵🇱

Szczecin, Poland

Sf. loan cel Nou, Emergency County Hospital

🇷🇴

Suceava, Romania

OncoMed

🇷🇴

Timisoara, Romania

Regional Oncology Center

🇷🇺

Penza, Russian Federation

Chelyabinsk Regional Oncology Center

🇷🇺

Chelyabinsk, Russian Federation

Clinical County Hospital

🇷🇴

Sibiu, Romania

Buryatia Republican Oncology Center

🇷🇺

Ulan-Ude, Buryatia, Russian Federation

Republican Oncology Center of the Ministry of Healthcare of Karelia Republic

🇷🇺

Petrozavodsk, Karelia Republic, Russian Federation

Clinical Oncology Center

🇷🇺

Kazan, Tatarstan Republic, Russian Federation

City Hospital #1

🇷🇺

Cherepovets, Russian Federation

Kaluga Regional Oncology Center

🇷🇺

Kaluga, Russian Federation

Regional Clinical Oncology Center

🇷🇺

Kirov, Russian Federation

Krasnodar Clinical Oncology

🇷🇺

Krasnodar, Russian Federation

Blokhin Russian Oncology Research Center

🇷🇺

Moscow, Russian Federation

Orel Oncology Center

🇷🇺

Orel, Russian Federation

Orenburg Regional Clinical Oncology Center

🇷🇺

Orenburg, Russian Federation

Pyatigorsk Affiliate of Stavropol Regional Clinical Oncology Center

🇷🇺

Pyatigorsk, Russian Federation

Ogarev Mordovian State University

🇷🇺

Saransk, Russian Federation

St. Petersburg City Multifield Hospital #2

🇷🇺

St. Petersburg, Russian Federation

City Clinical Oncology Center, Thoracic Oncology Department #6

🇷🇺

St. Petersburg, Russian Federation

Public Treatment and Prevention Institution Mariupol City Interdistrict Oncology Center

🇺🇦

Mariupol, Ukraine

Tambov Regional Oncology Center

🇷🇺

Tambov, Russian Federation

Tomsk Regional Oncology Center

🇷🇺

Tomsk, Russian Federation

Voronezh Regional Clinical Oncology Center

🇷🇺

Voronezh, Russian Federation

Regional Clinical Oncology Hospital

🇷🇺

Yaroslavl, Russian Federation

Primorsky Regional Oncology Center

🇷🇺

Vladivostok, Russian Federation

Republican of Clinical Hospital, Mariy-El Republican

🇷🇺

Yoshkar-Ola, Russian Federation

Multiprofile Hospital for Active Treatment "St. Marina"

🇧🇬

Varna, Bulgaria

Shatabdi Superspeciality Hospital

🇮🇳

Nasik, Maharashtra, India

District Dispensary for Cancer Diseases with Inpatient Hospital Plovdiv

🇧🇬

Plovdiv, Bulgaria

University of Szeged

🇭🇺

Szeged, Hungary

Inter-district Dispensary for Cancer Disease w/Inpatient Hospital "Dr. Marko Markov", Varna

🇧🇬

Varna, Bulgaria

Curie Centre of Oncology

🇮🇳

Bangalore, India

Lakeshore Hospital and Research Center

🇮🇳

Kochin, Kerala, India

Oncology Center

🇷🇺

Sochi, Russian Federation

St. Petersburg Pavlov State Medical University

🇷🇺

St. Petersburg, Russian Federation

Clinical Emergency County Hospital Constanta

🇷🇴

Constanta, Romania

Inter-district Dispensary for Cancer Diseases w/Inpatient Hospital

🇧🇬

Shumen, Bulgaria

Altai Regional Oncology Center

🇷🇺

Barnaul, Russian Federation

ISIS Clinica Especializada

🇦🇷

Santa Fe, Argentina

Clinic for Pulmonary Diseses "Jordanovac"

🇭🇷

Zagreb, Croatia

Institute of Post Graduate Medical Education and Research

🇮🇳

Kolkata, India

Jaslok Hospital and Research Centre

🇮🇳

Mumbai, India

Tata Memorial Centre

🇮🇳

Mumbai, India

Institution of Healthcare "Grodno Regional Clinical Hospital

🇧🇾

Grodno, Belarus

Kidwai Memorial Institute of Oncology

🇮🇳

Bangalore, Karnataka, India

Silesian Medical University in Katowice

🇵🇱

Zabrze, Dolny Slask, Poland

Dr. Bieganski Memorial Regional Specialsitic Hospital

🇵🇱

Grudziadz, Poland

Regional Hospital, Department of Pulmonary Diseases and Chemotherapy

🇵🇱

Krakow, Poland

Department of Pulmonology, Voyvodship Specialsitic Hospital in Radom

🇵🇱

Radom, Poland

Department of Clinical Oncology, SP ZOZ, Yoyvodship Specialistic Hospital

🇵🇱

Torun, Poland

Prof. Dr. Ion Chiricuta, Institute of Oncology Cluj-Napoca

🇷🇴

Cluj-Napoca, Cluj, Romania

Baia Mare "Constantin Opris" County Emergency Hospital

🇷🇴

Baia Mare, Maramures County, Romania

Bucharest Institute of Oncology

🇷🇴

Bucharest, Romania

Prof. Dr. Ion Chircuta, Oncology Institute

🇷🇴

Cluj-Napoca, Romania

Schuller Municipal Hospital Ploiesti-Medical Oncology Department

🇷🇴

Ploiesti, Romania

Kazan Oncology Center

🇷🇺

Kazan, Tatarstan Republic, Russian Federation

Arkhangelsk Regional Clinical Oncology Center

🇷🇺

Arkhangelsk, Russian Federation

Sverdlovsk Regional Oncology Center

🇷🇺

Ekaterinburg, Russian Federation

Ivanovo Regional Oncology Center

🇷🇺

Ivanovo, Russian Federation

Republican Clinical Oncology Center of the Republic of Udmurtia

🇷🇺

Izhevsk, Russian Federation

Kurst Regional Oncology Center

🇷🇺

Kurst, Russian Federation

Lipetsk Regional Oncology Center

🇷🇺

Lipetsk, Russian Federation

State Higher Education Institution Saratov State Medical University under the Federal Agency for Healthcare and Social Development

🇷🇺

Saratov, Russian Federation

Pavlov St. Petersburg State Medical University, Pulmonology Research Institute

🇷🇺

St. Petersburg, Russian Federation

© Copyright 2025. All Rights Reserved by MedPath